Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo

Executive Summary

The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.


Related Content

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?
How Will Novel Agents Impact The HIV Market?
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
TaiMed's Trogarzo Is US FDA's First HIV/AIDS Breakthrough Approval
10 First Approvals To Look Out For In 2018
Confidence Builds For Theratechnologies' Game-Changing HIV Monoclonal
Novel Antibody Products Ring The Treatment Changes In HIV
ViiV Buys Promising New Mechanisms In HIV From BMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts